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To the Editor, 
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare entity with initial descriptions in 
the mid 1990’s.1 It typically affects elderly patients with a slight male predominance (M:F ratio 
2-3:1).2,3 Clinically, BPDCN is characterized by abrupt onset of rapidly progressive nodules or 
ecchymotic plaques with concurrent or subsequent involvement of the bone marrow and 
peripheral blood.3 Prognosis is dismal.2 Histopathologically, the neoplastic infiltrate is composed 
of monomorphous medium-sized to large cells expressing CD4, CD56, CD123, and TCL1.2,4  
 The association of non-melanoma skin cancer (NMSC) with hematolymphoid 
malignancy is well documented, most frequently involving chronic lymphocytic leukemia (CLL) 
seen incidentally in biopsy or excision specimen of squamous cell carcinoma or basal cell 
carcinoma (BCC).5 Occasionally such observations may lead to the initial diagnosis of the 
hematolymphoid malignancy.6,7  
 We recently encountered the case of a 74-year-old man without any history of 
hematolymphoid malignancy, who underwent excision of a skin tumor on his left forearm. 
Clinical impression was BCC. Histopathologic examination confirmed a BCC with nodular and 
focally infiltrative growth patterns. In addition, there was a dense multinodular hematolymphoid 
infiltrate in the surrounding dermis and superficial subcutis with accentuation around adnexal 
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structures and blood vessels (Figure 1A). The majority of these cells were medium-sized with 
scant to moderate amount of cytoplasm, oval to irregular nuclei, and mostly fine chromatin. 
Some of these cells contain eccentrically located nuclei imparting a plasmacytoid morphology 
(Figure 1B).   
 By immunohistochemistry, the atypical hematolymphoid cells were diffusely and 
strongly positive for CD45, CD4 (Figure 1C), CD56 (Figure 1D), CD123 (Figure 1E), TCL1, 
and Bcl-2, and were weakly positive for CD2. These cells were diffusely negative for CD3, CD5, 
CD8, CD20, CD13, CD15, CD117, and myeloperoxidase (MPO) (Figure 1F). Ki-67 revealed a 
proliferation index of approximately 30% within the infiltrate.  
A diagnosis of BCC with concomitant BPDCN was rendered. This diagnosis was 
unexpected, and the patient was subsequently referred to Oncology for further work-up and 
treatment. 
 Although cutaneous epithelial neoplasms are commonly associated with at least mild 
inflammation, a hematolymphoid malignancy should be suspected when the infiltrate is 
unusually dense or extensive, and should prompt clinical correlation and immunohistochemical 
workup. As mentioned above, CLL represents the most common leukemic infiltrate seen in 
conjunction with NMSC. In our case, the presence of medium-sized cells, their fine rather than 
condensed chromatin, and the CD20- CD5- immunophenotype excluded a diagnosis of CLL. 
While CD56 expression may raise the possibility of an extranodal NK/T cell lymphoma, the 
coexpression of CD4 and CD123 as well as the negative staining for CD3 would speak against 
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this entity. Lastly, the lack of staining for myeloid markers (CD13, CD15, CD117, MPO) speaks 
against a myeloid leukemic infiltrate. It should be noted, however, that some cases of acute 
myeloid leukemia (AML), especially those with monocytic differentiation, may share a similar 
immunophenotype with BPDCN (CD4+ CD56+ CD123+ MPO-), which will require additional 
immunohistochemical markers and potentially molecular analysis for distinction.8-10 Two studies 
have concluded that coexpression of all four plasmacytoid dendritic cell markers: CD4, CD56, 
CD123, and TCL1, as seen in our case, would effectively confirm a diagnosis of BPDCN and 
distinguish it from most cases of MPO- myeloid leukemia cutis.3,8 Another study has shown a 
similar utility of TCF4 in this differential diagnosis.11 
 To the best of our knowledge, this is the first reported case of coexisting NMSC and 
BPDCN. Given its rarity, we favor that this phenomenon is purely coincidental (“collision 
tumor”). While most dermatopathologists are aware of the occasional finding of CLL infiltrate in 
excision specimens for NMSC, our case highlights the importance of keeping a broad differential 
diagnosis and performing immunohistochemical workup to rule out other hematolymphoid 
neoplasms. Correct identification of an aggressive hematolymphoid malignancy such as BPDCN, 
especially as an initial diagnosis, carries enormous clinical implications.  
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Figure Legend 
Figure 1. Skin excision from the left forearm. (A) An ulcerated nodule of basal cell carcinoma 
infiltrates the superficial to mid dermis (yellow circle). The tumor is associated with a brisk 
hematolymphoid infiltrate accentuated around blood vessels and adnexal structures in the 
surrounding dermis and superficial subcutis (H&E ×20). (B) High magnification of the 
hematolymphoid infiltrate reveals a predominance of medium-sized cells with scant to moderate 
amount of amphophilic cytoplasm, oval to irregular nuclei, and mostly fine chromatin. Some of 
these cells contain eccentric nuclei imparting a plasmacytoid morphology (H&E ×600). C) CD4 
is diffusely positive in the infiltrate (×20). D) CD56 also shows diffuse positivity in the infiltrate, 
as well as patchy staining in the basal cell carcinoma (×20). E) CD123 similarly shows diffuse 
staining (×20). F) The infiltrate is negative for myeloperoxidase (×20). 
This article is protected by copyright. All rights reserved.
Incidental diagnosis of blastic plasmacytoid dendritic cell neoplasm in skin excision for 
basal cell carcinoma 
 
Jayson Miedema1, Shane R. Starr2, May P. Chan1,3 
 
1Department of Pathology, University of Michigan, Ann Arbor, MI 
2McLaren Bay Region Hospital, Bay City, MI 
3Department of Dermatology, University of Michigan, Ann Arbor, MI 
 
Correspondence: 
May P. Chan, MD 
University of Michigan Department of Pathology 
Medical Science I, M3261 
1301 Catherine Street 
Ann Arbor, MI 48109 
Tel: (734)764-4460 
Fax: (734)764-4690 
Email: mpchan@med.umich.edu 
 
 
Keywords:  
Blastic plasmacytoid dendritic cell neoplasm, basal cell carcinoma, CD123 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
Fig1.tif
This article is protected by copyright. All rights reserved.
